FR167653 free base is a selective p38 MAPK inhibitor with oral activity, used to suppress TNF-α and IL-1β production by specifically inhibiting p38 MAPK activity; it is applicable in the treatment of inflammatory conditions, mitigation of trauma, and reduction of ischemia/reperfusion injury; in vivo studies show it significantly reduces acute tubular necrosis in murine models of ischemia-reperfusion injury.